NTLA EBITDA Growth
Intellia Therapeutics Inc · EBITDA Growth
NTLA EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported16.95%period ending
NTLA TTM EBITDA YoY % (-150.19% → 16.95%)
Year-over-year change
High-resolution chart · PNG
NTLA ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| 16.9493% | |
| 25.4122% | |
| 20.9002% | |
| 15.3812% | |
| 5.7886% | |
| -8.3138% | |
| -7.7337% | |
| -12.8227% | |
| -12.0579% | |
| -12.6587% | |
| -1.2006% | |
| -4.4414% | |
| -13.243% | |
| -16.8924% | |
| -78.6281% | |
| -95.1824% | |
| -119.2791% | |
| -151.7462% | |
| -100.5197% | |
| -89.2362% | |
| -55.7694% | |
| -30.8276% | |
| -29.2843% | |
| -27.7626% | |
| -26.3576% | |
| -25.4466% | |
| -16.6169% | |
| -1.4609% | |
| -9.8785% | |
| -15.5976% | |
| -29.8148% | |
| -70.9526% | |
| -82.4417% | |
| -105.4811% | |
| -114.3326% | |
| -104.239% | |
| -108.7414% | |
| -99.9132% | |
| -137.4054% | |
| -118.3429% | |
| -150.1867% |